摘要
The lack of rapid and efficient diagnostics impedes largely the epidemic control of multidrug-resistant tuberculosis, and might misguide the therapeutic strategies as well. This study aimed to identify novel multidrug-resistant tuberculosis biomarkers to improve the early intervention, symptomatic treatment and control of the prevalence of multidrug-resistant tuberculosis. The serum small molecule metabolites in healthy controls, patients with drug-susceptible tuberculosis, and patients with multidrug-resistant tuberculosis were screened using ultra-high-performance liquid chromatography combined with quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS). The differentially abundant metabolites were filtered out through multidimensional statistical analysis and bioinformatics analysis. Compared with drug-susceptible tuberculosis patients and healthy controls, the levels of 13 metabolites in multidrug-resistant tuberculosis patients altered. Among them, the most significant changes were found in N1-Methyl-2-pyridone-5-carboxamide (N1M2P5C), 1-Myristoyl-sn-glycerol-3-phosphocholine (MG3P), Caprylic acid (CA), and D-Xylulose (DX). And a multidrug-resistant tuberculosis/drug-susceptible tuberculosis differential diagnostic model was built based on these four metabolites, achieved the accuracy, sensitivity, and specificity of 0.928, 86.7%, and 86.7%, respectively. The enrichment analysis of metabolic pathways showed that the phospholipid remodeling of cell membranes was active in multidrug-resistant tuberculosis patients. In addition, in patients with tuberculosis, the metabolites of dipalmitoyl phosphatidylcholine (DPPC), a major component of pulmonary surfactant, were down-regulated. N1M2P5C, MG3P, CA, and DX may have the potential to serve as novel multidrug-resistant tuberculosis biomarkers. This research provides a preliminary experimental basis to further investigate potential multidrug-resistant tuberculosis biomarkers.
学科与关键词
- Serum proteins TGFBI, PCSK9, and CCL14 are potential biomarkers for different traditional Chinese medicine syndromes of multidrug-resistant tuberculosisHu, Yu-Ting; Yi, Wen-Jing; Jiang, Ting-Ting; Tu, Hui-Hui; Wei, Li-Liang; Shi, Li-Ying; Liu, Chang-Ming; Chen, Jing; Han, Yu-Shuai; Gan, Lin; Li, Zhi-Bin; Huang, Huai; Li, Ji-Cheng*Anatomical Record, 2020, 303(8): 2131-2143.被引 4
- Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical managementThu, Nguyen Quang; Tien, Nguyen Tran Nam; Yen, Nguyen Thi Hai; Duong, Thuc-Huy; Long, Nguyen Phuoc*; Nguyen, Huy Truong*Journal of Pharmaceutical Analysis, 2024, 14(1): 16-38.被引 2
- The quest for biomarkers in tuberculosisParida, Shreemanta K.*; Kaufmann, Stefan H. E.Drug Discovery Today, 2010, 15(3-4): 148-157.被引 90
